Tanya Wallace is the vice president and head of translational science at Neumora Therapeutics, a clinical-stage neuroscience biotechnology company advancing a pipeline of targeted therapeutics for treating brain disorders. After completing her PhD in neuroscience and subsequent postdoctoral studies, she began her career working within the pharma, biotech and non-profit organizational sectors, where she has had roles with increasing responsibilities within Bristol Myers Squibb, Roche, SRI International and BlackThorn Therapeutics. During this time, she has led teams that have successfully advanced novel molecules from early discovery stages through development and filed multiple Investigational New Drug (IND) applications for clinical investigation. She currently leads a cross-disciplinary team of biologists working with internal and external collaborators to characterize novel molecules in preclinical models to support transition into early clinical development for psychiatric and neurological disorders.